← Leaderboards
Lauren Ashley Cowart
Va Veterans Administration Hospital
$5,442,995
Attributed
$6,752,003
Total exposure
13
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,752,003 · 11
VA$0 · 2
By mechanism
R01$5,183,588 · 3
P20$593,491 · 4
R21$437,821 · 1
T32$265,507 · 1
P30$261,296 · 1
R13$10,300 · 1
Top collaborators
- David John Montefusco2 shared
- Amy S Paller2 shared
- Brian W Wattenberg2 shared
- William Gregory Hundley1 shared
- Fadi N Salloum1 shared
Most similar at Va Veterans Administration Hospital
Same institution · by research overlap
- Charles E Chalfant$17,297,423
Others in their field
Top investigators on “Sphingolipids”
- Yusuf Awni Hannun · Medical University Of South Carolina$30,274,744
- Timothy Tun Hla · Boston Children'S Hospital$22,231,469
- Sarah Spiegel · Virginia Commonwealth University$19,116,930
- Besim Ogretmen · Medical University Of South Carolina$18,386,608
- Julie D Saba · University Of California, San Francisco$15,245,252
- Charles E Chalfant · Va Veterans Administration Hospital$12,100,824
Research focus
SphingolipidsLipidsRegulationPathway InteractionsBaseMetabolismCellsMediatingInflammationCardiovascular DiseasesIn VivoAttenuatedPreventFatty AcidsSignal TransductionObesityResponseProductionEnzymesMouse ModelPathologyDiabetes MellitusSphingosine 1-PhosphateAnabolism
Grant awards (43)
Sphingolipid Biosynthesis in the Healthy and Diseased Epidermal Barrier$662,930
R01 · FY2025 · AR
Multi-Disciplinary Training Program in Translational Cardiovascular Research$265,507
T32 · FY2025 · HL
Sphingolipids in the Pathophysiology of Obesity and Diabetes$0
I01 · FY2025 · VA · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2025 · VA · contact PI
Sphingolipid Biosynthesis in the Healthy and Diseased Epidermal Barrier$706,710
R01 · FY2024 · AR
Novel sphingolipid metabolites in myocardial ischemia$388,125
R01 · FY2024 · HL · contact PI
Atypical sphingolipids in alcoholic liver disease$229,246
R21 · FY2024 · AA · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2024 · VA · contact PI
Sphingolipids in the Pathophysiology of Obesity and Diabetes$0
I01 · FY2024 · VA · contact PI
Novel sphingolipid metabolites in myocardial ischemia$388,125
R01 · FY2023 · HL · contact PI
Atypical sphingolipids in alcoholic liver disease$208,575
R21 · FY2023 · AA · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2023 · VA · contact PI
Sphingolipids in the Pathophysiology of Obesity and Diabetes$0
I01 · FY2023 · VA · contact PI
Novel sphingolipid metabolites in myocardial ischemia$388,125
R01 · FY2022 · HL · contact PI
Sphingolipids in the Pathophysiology of Obesity and Diabetes$0
I01 · FY2022 · VA · contact PI
Novel sphingolipid metabolites in myocardial ischemia$388,125
R01 · FY2021 · HL · contact PI
Lipidomics Shared Resource$79,463
P30 · FY2021 · CA · contact PI
Novel sphingolipid metabolites in myocardial ischemia$388,125
R01 · FY2020 · HL · contact PI
Lipidomics Shared Resource$57,691
P30 · FY2020 · CA · contact PI
Roles of Sphingolipids in the Pathophysiology of Obesity and Diabetes$0
I01 · FY2020 · VA · contact PI
Lipidomics Shared Resource$62,113
P30 · FY2019 · CA · contact PI
Roles of Sphingolipids in the Pathophysiology of Obesity and Diabetes$0
I01 · FY2019 · VA · contact PI
Sphingolipids in Diabetic Cardiomyopathy$383,930
R01 · FY2018 · HL · contact PI
Lipidomics Shared Resource$62,029
P30 · FY2018 · CA · contact PI
Society for Heart and Vascular Metabolism, 16th Annual Meeting$10,300
R13 · FY2018 · HL · contact PI
Roles of Sphingolipids in the Pathophysiology of Obesity and Diabetes$0
I01 · FY2018 · VA · contact PI
Sphingolipids in Diabetic Cardiomyopathy$229,607
R01 · FY2017 · HL · contact PI
Sphingolipids in Diabetic Cardiomyopathy$144,143
R01 · FY2017 · HL · contact PI
Roles of Sphingolipids in the Pathophysiology of Obesity and Diabetes$0
I01 · FY2017 · VA · contact PI
Sphingolipids in Diabetic Cardiomyopathy$373,750
R01 · FY2016 · HL · contact PI
Roles of Sphingolipids in the Pathophysiology of Obesity and Diabetes$0
I01 · FY2016 · VA · contact PI
Sphingolipids in Diabetic Cardiomyopathy$368,143
R01 · FY2015 · HL · contact PI
Roles of Sphingolipids in the Pathophysiology of Obesity and Diabetes$0
I01 · FY2015 · VA · contact PI
Sphingolipids in Diabetic Cardiomyopathy$373,750
R01 · FY2014 · HL · contact PI
Roles of Sphingolipids in the Pathophysiology of Obesity and Diabetes$0
I01 · FY2014 · VA · contact PI
Roles of Sphingolipids in the Pathophysiology of Obesity and Diabetes$0
I01 · FY2013 · VA · contact PI
SUBSTRATE SUPPLY IN DE NOVO SPHINGOLIPID SYNTHESIS: REGULATION/IMPACT ON CHEMOTH$72,285
P20 · FY2011 · RR · contact PI
Sphingolipid-mediated skeletal muscle pathology in response to free fatty acids.$0
I01 · FY2011 · VA · contact PI
Sphingolipid-mediated skeletal muscle pathology in response to free fatty acids.$0
I01 · FY2011 · VA · contact PI
SUBSTRATE SUPPLY IN DE NOVO SPHINGOLIPID SYNTHESIS: REGULATION/IMPACT ON CHEMOTH$72,993
P20 · FY2010 · RR · contact PI
SUBSTRATE SUPPLY IN DE NOVO SPHINGOLIPID SYNTHESIS: REGULATION/IMPACT ON CHEMOTH$233,593
P20 · FY2009 · RR · contact PI
Sphingolipid-mediated skeletal muscle pathology in response to free fatty acids.$0
I01 · FY2009 · VA · contact PI
SUBSTRATE SUPPLY IN DE NOVO SPHINGOLIPID SYNTHESIS: REGULATION/IMPACT ON CHEMOTH$214,620
P20 · FY2008 · RR · contact PI